(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 13.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Aurinia Pharmaceuticals's revenue in 2025 is $260,111,000.On average, 3 Wall Street analysts forecast AUPH's revenue for 2025 to be $35,739,527,812, with the lowest AUPH revenue forecast at $35,322,788,669, and the highest AUPH revenue forecast at $36,356,080,605. On average, 4 Wall Street analysts forecast AUPH's revenue for 2026 to be $41,462,912,101, with the lowest AUPH revenue forecast at $37,448,605,837, and the highest AUPH revenue forecast at $46,832,476,171.
In 2027, AUPH is forecast to generate $49,698,972,795 in revenue, with the lowest revenue forecast at $45,951,874,509 and the highest revenue forecast at $58,788,387,835.